Literature DB >> 15047569

Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers.

Rachael Barber1, George S Baillie, Reinhard Bergmann, Malcolm C Shepherd, Ruth Sepper, Miles D Houslay, Gino Van Heeke.   

Abstract

The expression profile of a panel of 15 cAMP phosphodiesterase isoforms was determined for inflammatory cell types of relevance to chronic obstructive pulmonary disease (COPD). In particular, the expression profiles for bronchoalveolar macrophages, peripheral blood monocytes, T lymphocytes, and neutrophils from smokers with and without COPD were compared. The phosphodiesterase expression profile was also analyzed for peripheral blood monocytes, T lymphocytes, and neutrophils from nonsmokers and compared with smokers. Qualitative RT-PCR identified transcripts for PDE4A10, PDE4A7, PDE4B1, PDE4B2, PDE4D1, and PDE4D2 isoforms as well as transcripts for both PDE3B and PDE7A in T cells, monocytes, and macrophages in all subjects. Transcripts for PDE4B3 and PDE4D4 were not observed in any of the cell types investigated. PDE4C was detected in all cells analyzed except for T cells. The long PDE4A4, PDE4D3, and PDE4D5 isoforms exhibited cell type-specific expression patterns. Semiquantitative and real-time quantitative RT-PCR were used to analyze differential expression between disease states and between cell types. PDE4A4 was found significantly upregulated in lung macrophages from smokers with COPD when compared with control smokers. Furthermore, PDE4A4 as well as PDE4B2 transcripts were detected in higher amounts in peripheral blood monocytes of smokers when compared with nonsmokers. Finally, PDE4D5 and PDE4C were differentially regulated in lung macrophages when compared with monocytes of the same subjects, irrespective of the disease state. The data obtained suggest that PDE4A4 may be relevant as a macrophage-specific anti-inflammatory target for COPD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047569     DOI: 10.1152/ajplung.00384.2003

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  31 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

Review 3.  Phosphodiesterase inhibitors.

Authors:  Victoria Boswell-Smith; Domenico Spina; Clive P Page
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 4.  PDE4 inhibitors: current status.

Authors:  D Spina
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

5.  Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.

Authors:  J Milara; M Armengot; P Bañuls; H Tenor; Rolf Beume; E Artigues; J Cortijo
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

6.  Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory.

Authors:  Robbert Havekes; Alan J Park; Rosa E Tolentino; Vibeke M Bruinenberg; Jennifer C Tudor; Yool Lee; Rolf T Hansen; Leonardo A Guercio; Edward Linton; Susana R Neves-Zaph; Peter Meerlo; George S Baillie; Miles D Houslay; Ted Abel
Journal:  J Neurosci       Date:  2016-08-24       Impact factor: 6.167

7.  Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.

Authors:  A Buenestado; S Grassin-Delyle; F Guitard; E Naline; C Faisy; D Israël-Biet; E Sage; J F Bellamy; H Tenor; P Devillier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

8.  Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function.

Authors:  Hannah Murdoch; Suryakiran Vadrevu; Anke Prinz; Allan J Dunlop; Enno Klussmann; Graeme B Bolger; James C Norman; Miles D Houslay
Journal:  J Cell Sci       Date:  2011-06-07       Impact factor: 5.285

9.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.